WillItSurvive
Pharma and healthcare groups · China

Hansoh Pharmaceutical

Chinese maker of approved cancer, obesity and immune drugs sold at home and abroad.

Hard to displace
Assessed 26 July 2026 · Evidence as of 26 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 26 July 2026 · Checkable from 2026 · Every call on the record Checkpoint: NMPA decision on HS-10568 injection NDA
The call

Hansoh sells approved drugs that Western majors pay to license, while its real contest is with other Chinese biotech firms racing for the same reimbursement slots.

Hansoh Pharmaceutical makes new medicines for Chinese patients and has grown revenue and profit by roughly 22-27% per year. It is hard to copy because it owns patents, has clinical trial data, and gets approval from Chinese regulators, which takes years and money; Western competitors like Roche actually pay Hansoh to use its discoveries rather than build their own. AI can help find new drug ideas early on, but it cannot run human trials, get government approval, or manufacture pills, so AI alone is not a threat. The one thing that could hurt Hansoh is if US and China tensions make it harder for the company to license its drugs to Western companies, which brings in money and validates its science.

Why
01
AI pressure: AI-driven drug discovery platforms such as Insilico Medicine and Isomorphic Labs. AI speeds up molecule discovery for everyone, but trials, NMPA approval and NRDL listing still gate who actually gets paid. Could AI do the core job? Unlikely.
02
Bigger players: Hengrui Pharmaceuticals, BeiGene, Innovent, Akeso, Junshi and Zai Lab. These Chinese peers already sell competing drugs and chase the same Western licensing deals Hansoh depends on. Could a giant copy it? No, they are blocked.
03
What protects it. Approved drugs, NRDL reimbursement slots, patents and China trial data that regulators and distribution rules protect from copying.
What would change this call
Hengrui, Innovent, or BeiGene announce a major Western out-licensing deal in Hansoh's therapeutic areas within 12 months. Would show peers eroding Hansoh's BD/licensing advantage with Western pharma.
Q4 2026 NRDL price negotiation results for Hansoh's top-3 products. A steep cut would show pricing power weakening versus peers in reimbursed categories.
Hansoh's H1 2026 earnings (due 18 Aug 2026) BD/licensing income line. A second consecutive decline would show deal-flow momentum stalling versus rivals.
Key numbers
  • FY2025 revenue RMB 15,028M, up 22.6% YoY (2025-12-31)
  • FY2025 profit RMB 5,555M, up 27.1% YoY (2025-12-31)
  • Regeneron deal: $80M upfront, up to $1.93B milestones (2025-06-02)
Named risks
  • US-China geopolitical friction could restrict outbound licensing deal flow to Western pharma partners. Severity: high
  • NRDL price renegotiation cycle could cut pricing on top reimbursed products. Severity: medium
  • Binary Phase 3 or regulatory outcomes on licensed assets like HS-20093 or HS-20094 could disappoint. Severity: medium
  • Domestic peers such as Hengrui, BeiGene and Innovent compete intensely for global licensing deals and pipeline talent. Severity: medium
  • Convertible bond refinancing and conversion price adjustments could dilute shareholders. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Jiangsu HengruicontestingBroadest domestic pipeline and major outbound BD engine, e.g. Kailera obesity spin out, per 2026-05-14 analysis
BeiGenecontestingGlobal commercialization leader with Tevimbra approved in US and EU as of 2026-05-07 analysis
Innovent Biologicscontesting2026 deals with Pfizer and Eli Lilly worth combined roughly $19B headline value, per 2026-06-11 analysis
GSKgaining onLicensed HS-20093 from Hansoh, which received FDA Breakthrough Therapy Designation 2024-08-20 and EMA PRIME 2024-12
Regenerongaining onIn-licensed HS-20094 from Hansoh for $80M upfront plus up to $1.93B milestones, 2025-06-02
Questions people ask
Is Hansoh Pharmaceutical profitable in 2025?
Yes. Hansoh reported FY2025 revenue of RMB 15,028 million, up 22.6% year on year, with profit for the year rising 27.1% to RMB 5,555 million and basic EPS up 26.4% to RMB 0.93, per its 2025 Annual Results Announcement dated 2026-03-29.
Who are Hansoh Pharmaceutical's biggest competitors?
Hansoh's closest rivals are fellow Chinese innovative drug makers Jiangsu Hengrui, BeiGene, Innovent Biologics, Junshi Biosciences, Akeso and Zai Lab, all competing for domestic pipeline leadership and global licensing deals as of 2026.
Could AI replace Hansoh Pharmaceutical's drug development work?
Not fully. AI mainly accelerates early target identification and molecule screening; Hansoh's NRDL-reimbursed commercial drugs, certified manufacturing, and clinical trial and regulatory approvals, the parts global majors pay billions to license, remain outside AI's reach as of 2026.
Who owns Hansoh Pharmaceutical?
Hansoh Pharmaceutical (SEHK: 3692) is publicly listed on the Hong Kong Stock Exchange since 14 June 2019; Yahoo Finance lists it as a subsidiary of Stellar Infinity Company Ltd, believed tied to founder and chairwoman Zhong Huijuan's family holding vehicle, as of 2025-05-01.
What major licensing deals has Hansoh Pharmaceutical signed recently?
In June 2025 Hansoh out-licensed ex-China rights to HS-20094, a GLP-1/GIP agonist, to Regeneron for $80 million upfront plus up to $1.93 billion in milestones, and in October 2025 signed a separate license agreement with Roche.
How is Hansoh Pharmaceutical's stock performing in 2026?
Hansoh's shares traded roughly HKD 32 to 36 in H1 2026 with a 52-week range of about HKD 17.10 to 44.22, and market capitalization was reported around HKD 195 billion as of 2026-07-26 per gurufocus.com.
Timeline
  • 2026-07-14Out-licensed HS-20118 to Avere Therapeutics for $120M upfront, up to $2.18B milestones
  • 2026-06NDA for HS-10568 injection accepted by China's NMPA
  • 2026-03-29FY2025 results: revenue RMB 15,028M (+22.6%), profit RMB 5,555M (+27.1%)
  • 2026-01Issued new HKD 4,680M convertible bonds due 2033
  • 2025-10-17Entered license agreement with Roche
  • 2025-06-02Out-licensed HS-20094 to Regeneron for $80M upfront, up to $1.93B milestones
  • 2024-12GSK's HS-20093 received EMA PRIME designation
  • 2024-08-20GSK's HS-20093 received FDA Breakthrough Therapy Designation
  • 2022-08Added to Hang Seng Index
  • 2019-06-14Listed on Hong Kong Stock Exchange main board
Revision history
26 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources